Their use in clinical practice is likely to evolve with potential future use as adjuvant treatment for RET fusion–positive NSCLC as well as expanded use across multiple solid tumors with RET mutations/fusions, as genomic testing becomes more widespread and eligible patients more readily identified. The gene discussed is RET; the disease is non-small cell lung carcinoma.